Journals / Respiratory Case Reports / 2018 / Cilt: 7 - Sayı: 3

Paclitaxel Associated Lung Toxicity in a Patient with Invasive Urothelial Carcinoma

İnvazif Ürotelyal Karsinomlu Hastada Paklitaksel’e Bağlı Akciğer Toksisitesi

Pages
154–157
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case was presented because lung toxicity due to paclitaxel is rare.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Paclitaxel is an anti-cancer drug that induces mitotic arrest via microtubule hyperstabilization, but which also causes side effects due to its hydrophobicity and cellular promiscuity.
📊
Key Findings & Data:A 71-year-old male patient presented at the polyclinic with dyspnea present for 2 weeks.
💡
Conclusion & Impact:This case was presented because lung toxicity due to paclitaxel is rare.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Paclitaxel is an anti-cancer drug that induces mitotic arrest via microtubule hyperstabilization, but which also causes side effects due to its hydrophobicity and cellular promiscuity. A 71-year-old male patient presented at the polyclinic with dyspnea present for 2 weeks. In November 2016, the patient had been diagnosed with bladder-derived invasive urothelial bladder carcinoma and received 2 cycles of paclitaxel therapy. High-resolution computed tomography revealed peripheral-subpleural interlobular septal thickening, reticular densities, ground-glass density areas, and peripheral focal consolidation in both lungs, particularly on the right. Peripheral traction bronchiectasis was also observed, especially in the posterobasal segments of both lower lobes. Bronchial lavage revealed hyperplastic reserve cells, macrophages, bacterial clusters, and polymorphonuclear leukocytes, but no atypical cell were observed. The infection was ruled out. Chemotherapy was terminated and methylprednisolone (0.75 mg/kg) was initiated. Regression was observed in a control posteroanterior chest graphy after 1 month of steroid therapy. This case was presented because lung toxicity due to paclitaxel is rare.

Özet

Paklitaksel, mikrotübül hiperstabilizasyon yoluyla mitotik duraklamayı başlatan bir anti-kanser ilacı olup hidrofobikliği ve hücresel seçiciliği olmaması nedeniyle yan etkilere neden olmaktadır. Yetmiş bir yaşında erkek hasta göğüs hastalıkları polikliniğine 2 haftadır olan nefes darlığı şikâyeti ile başvurdu. Kasım 2016 ‘da mesane kaynaklı invazif ürotelyal mesane karsinom tanısı alan hasta 2 kür Paklitaksel tedavisi almıştı. Hastanın posteroanterior akciğer grafisinde bilateral periferik infiltrasyonları mevcuttu. Yüksek Rezolüsyonlu Bilgisayarlı Tomografide her iki akciğerde sağda daha belirgin olmak üzere periferalsubplevral interlobüler septal kalınlaşmalar, retiküler dansiteler, buzlu cam yoğunluk alanları, periferal yamasal fokal konsolide alanlar izlendi. Özellikle her iki alt lob posterobazal segmentlerde periferal yerleşimli traksiyon bronşektaziler izlendi. Bronş lavajında; hiperplastik rezerv hücreler, makrofajlar, bakteri kümeleri, PNL izlendi, atipik hücre gözlenmedi. Hastada mevcut bulgularla Paklitaksel toksisitesi düşünüldü, kemoterapisi sonlandırıldı ve metilprednizolon tedavisi başlandı. Metilprednizolon tedavisinin birinci ayında kontrol akciğer grafisinde regresyon izlendi. Paklitaksel’e bağlı akciğer toksisitesisinin nadir görülmesi nedeniyle bu olguyu sunduk.

🔖

Cite This Article

ERÇELİK, M., ATAOĞLU, Ö., GÜLHAN, P. Y., AYTEKİN, F., ELVERİŞLİ, M. F., EŞBAH, O., BALBAY, E. G. (2018). Paclitaxel Associated Lung Toxicity in a Patient with Invasive Urothelial Carcinoma. Respiratory Case Reports, Cilt: 7 - Sayı: 3, 154–157. https://ajindex.com/articles/302419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, et al. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 1997;54:298-303. [CrossRef] 2. Rowinsky EK, Donehower RC. Paclitaxel (taksol). N Engl J Med 1995; 332:1004-14. 3. Foucher P, Camus P. Groupe d'Etude de la Pathologie Pulmonaire Iatrogene. The drug-induced respiratory disease; 2014 [update 2014 June]. Available from: http://www.pneumotox.com. 4. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992; 19: 508–20. 5. Wong P, Leung AN, Berry GJ, Atkins KA, Montoya JG, Ruoss SJ, et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 2001; 176:718–20. [CrossRef] 6. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology 2002; 224:852-60. [CrossRef] 7. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Muller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292-9. [CrossRef] 8. Ichikado K, Suga M, Muller NL, Taniguchi H, Kondoh Y, Akira M, et al. Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med 2002; 165:1551-6. [CrossRef] 9. Charpidou AG1, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, et al: Therapy-induced toxicity of the lungs: an overview. Anticancer Res 2009; 29:631-9. 10. Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185–91. [CrossRef] 11. Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxelrelated hypersensitivity reactions. Ann Oncol 1997; 8:611-4. [CrossRef] 12. Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol 1995; 13: 534-5. [CrossRef] 13. Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxelinduced acute bilateral pneumonitis. Ann Pharmacother 1997; 31:1471-4. [CrossRef] 14. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small cell lung cancer. J Clin Oncol 1996; 14: